Supported by Gilead Sciences Europe Ltd who provided funding for this content and is intended for healthcare professionals. Gilead Sciences Europe Ltd was not involved in the creation of this content.
The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Gilead Sciences Europe Ltd or EMJ. Note that not all treatments discussed in this episode may have received market approval. Please refer to your local marketing authorisation and prescribing practices for guidance. The speakers received honoraria.
Spotify | Apple | Amazon Music | Download MP3 (40:41 mins)
Experts in hepatology Thomas Berg, Palak Trivedi, and patient advocate Robert Mitchell-Thain explore the recent advancements and key highlights in primary biliary cholangitis (PBC) presented at the Association for the Study of Liver Diseases (AASLD) 2024 conference.
In this episode, they explore:
-
The burden of PBC, including its associated symptoms
-
The unmet needs of individuals living with PBC
-
Key insights on advancing education about emerging treatments for PBC
Speakers
Host
Hannah Moir1
Experts
Thomas Berg2
Palak Trivedi3
Robert Mitchell-Thain4
1. EMJ, Head Medical Writer, Moderator, and Educator, EMJ, London, UK. Senior Fellow (Associate Professor in Health & Exercise Prescription), Faculty of Health, Science, Social Care and Education, Kingston University, London, UK.
2. MD, Professor of Medicine, Head of Division of Hepatology, and Deputy Director of Department of Medicine II, Leipzig University Medical Center, Germany.
3. Clinician Scientist in the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), Associate Professor and Honorary Consultant Hepatologist at the Centre for Liver and Gastrointestinal Research, Department of Immunology and Immunotherapy at the University of Birmingham, in the UK.
4. Patient advocate and service provider, and CEO of the PBC Foundation, Edinburgh, UK
